Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 17 · above the Ichimoku cloud · RSI 95 (overbought) · MACD above its signal · at its 52-week high
None of the 29 investors followed here reported a position in TRVN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TRVN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for TRVN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.5 | 0.0 | 0.0 | 0.0 | -91.0 | 50.0 | 640.0 | -91.0 | 1100.0 | 450.0 | +450.0% | ||
| 2025 | 11.3 | -2.6 | -24.8 | 4.7 | -10.2 | -8.7 | -13.3 | -72.5 | -94.0 | -20.0 | 0.0 | 0.0 | −99.2% |
| 2024 | -11.2 | -9.3 | -20.8 | -13.0 | -2.5 | -44.1 | -2.8 | -25.7 | -5.1 | -48.1 | -12.9 | -11.2 | −91.7% |
| 2023 | 15.4 | -34.5 | -35.2 | -7.4 | 75.9 | -22.7 | 12.4 | -12.1 | -30.7 | -11.5 | 9.1 | 24.1 | −49.5% |
| 2022 | -6.7 | -15.8 | 20.2 | -46.1 | 5.2 | 32.8 | -40.1 | -13.0 | -29.0 | 11.9 | -19.4 | -58.6 | −90.2% |
| 2021 | 1.9 | -1.6 | -16.6 | -3.9 | 1.2 | -2.9 | -21.3 | -0.8 | -6.8 | -17.9 | -32.7 | -14.3 | −72.8% |
| 2020 | 4.8 | -18.9 | -20.7 | 30.5 | 75.7 | 15.4 | 54.7 | -23.7 | 68.9 | -12.4 | -4.2 | -14.7 | +154.5% |
| 2019 | 148.8 | 23.4 | 18.2 | -5.8 | -21.1 | -11.2 | -7.8 | -13.7 | 18.0 | -0.7 | -28.6 | 22.7 | +95.6% |
| 2018 | 1.9 | 9.8 | -8.4 | 13.4 | 0.5 | -23.0 | 6.9 | 16.9 | 17.8 | -56.9 | -30.5 | -32.3 | −73.1% |
| 2017 | 18.7 | -41.8 | -9.6 | -10.9 | -28.7 | -1.3 | 13.5 | -8.0 | 6.3 | -41.2 | 10.7 | -3.6 | −72.8% |
| 2016 | -30.7 | 15.0 | -1.2 | -5.8 | -6.0 | -13.9 | -0.5 | 8.1 | -0.4 | -27.7 | 12.3 | 7.3 | −44.0% |
| 2015 | -8.9 | -1.1 | 21.0 | -5.4 | 12.8 | -10.1 | -7.0 | 3.1 | 72.5 | -7.1 | 30.9 | -16.6 | +75.6% |
| 2014 | 22.8 | -1.5 | -36.3 | -12.4 | 28.7 | 21.2 | -13.7 | 8.6 | -9.5 | -10.2 | 14.6 | −8.0% |
No analyst coverage for this instrument.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
No recent headlines.